Skip to Main Content


Skip Nav Destination

Cancer Immunology Research 10th Anniversary Banner

Celebrating the 10th Anniversary:
A Message from Our Editors-in-Chief

We could not be prouder of all that Cancer Immunology Research has achieved in the past 10 years or be more grateful to the community for its support of the Journal during that time. In our editorial and a recent interview, we discussed the Journal's origins, how the Journal’s growth has mirrored that of the field of cancer immunology, and the immense potential that we see for future advances in this rich and vibrant field.

Read our editorial


A conversation with Editors-in-Chief Philip D Greenberg, MD and Robert D. Schreiber, PhD

There's no question that there's clinical applications now of cancer immunology, but that all of them are built on basic science studies and understanding how the immune system can interact with cancer.



Top Ten for Ten Years of Cancer Immunology Research

Read our collection of the most-cited research articles, based on citation rate from date of publication to January 2023, for each of the 10 years of Cancer Immunology Research's publication. Congratulations to the authors of these outstanding articles!

Photo of Mark J. Selby Photo of Alan J. Korman
Mark J. Selby and Alan J. Korman

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

The therapeutic potential of CTLA-4 blockade is evident in the ability of anti-CTLA-4 antibody to induce regression of established tumors. In an elegant set of experiments using a panel of murine immunoglobulin in various isotypes, Selby and colleagues delineated the mechanism of action of CTLA-4 blockade. Anti-CTLA-4 promotes antitumor activity by a selective reduction of intratumoral T-regulatory cells along with concomitant activation of T-effector cells.

Photo of Elizabeth A. Mittendorf
Elizabeth A. Mittendorf

PD-L1 Expression in Triple-Negative Breast Cancer

Using tissue microarrays containing 105 triplenegative breast cancer (TNBC) specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD-L1 expression, providing a rationale for therapeutic targeting of PD-L1 for TNBC.


Join the conversation on Twitter
@CIR_AACR   #CIRturns10

Keep up to date with 10th anniversary activities throughout the year!

Close Modal

or Create an Account

Close Modal
Close Modal